Congress Seeks Assurances 340B Program Benefits Vulnerable Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
An explanatory report on the appropriations bill suggests that the pharmaceutical industry is succeeding in efforts to convince Congress that the 340B drug discount program should be doing more to ensure patients directly benefit from the discounts.
You may also be interested in...
340B Providers Should Report How They Use Drug Savings, House Members Say
Energy and Commerce Committee Republican members indicate particular concern with knowing how hospitals use drug discount savings to improve patient care.
R&D Credit Retroactively Renewed For 2014, But It Stops There
Congress approved a tax-extenders bill that will retroactively renew the research and development tax credit for 2014 on a 76-16 vote, but the credit expires on Dec. 31.
340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs
A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.